An accelerated, clinical-grade protocol to generate high yields of type 1-polarizing messenger RNA–loaded dendritic cells for cancer vaccination
- 1 September 2018
- journal article
- research article
- Published by Elsevier in Cytotherapy
- Vol. 20 (9) , 1164-1181
Abstract
No abstract availableKeywords
Funding Information
- Ghent University Concerted Research Initiative (BOF24/GOA/027)
- Foundation Against Cancer, the Flemish League Against Cancer, Spearhead Research Programs and Ghent University Hospital Inter-University Attraction Poles
This publication has 52 references indexed in Scilit:
- Comparison of clinical grade type 1 polarized and standard matured dendritic cells for cancer immunotherapyVaccine, 2013
- A Spatially-Organized Multicellular Innate Immune Response in Lymph Nodes Limits Systemic Pathogen SpreadCell, 2012
- Induction of CD8+T-Cell Responses Against Novel Glioma–Associated Antigen Peptides and Clinical Activity by Vaccinations With α-Type 1 Polarized Dendritic Cells and Polyinosinic-Polycytidylic Acid Stabilized by Lysine and Carboxymethylcellulose in Patients With Recurrent Malignant GliomaJournal of Clinical Oncology, 2011
- CXCR3 ligands: redundant, collaborative and antagonistic functionsImmunology & Cell Biology, 2011
- Effect of multiple activation stimuli on the generation of Th1-polarizing dendritic cellsHuman Immunology, 2010
- Polarized dendritic cells as cancer vaccines: Directing effector-type T cells to tumorsSeminars in Immunology, 2010
- Single-Step Antigen Loading and Activation of Dendritic Cells by mRNA Electroporation for the Purpose of Therapeutic Vaccination in Melanoma PatientsClinical Cancer Research, 2009
- Identification of a dendritic cell receptor that couples sensing of necrosis to immunityNature, 2009
- A full scale comparative study of methods for generation of functional Dendritic cells for use as cancer vaccinesBMC Cancer, 2007
- Characterization of a Nontoxic Monophosphoryl Lipid AClinical Infectious Diseases, 1987